Abhishek Singla , MD
Associate Professor of Clinical
Medical Sciences Building
COM IM Pulmonary Division - 0564
Education
Doctor of Medicine : Maulana Azad Medical College, University of Delhi New Delhi, India, 2010 (Internal Medicine)
MBBS: University College of Medical Sciences, University of Delhi, New Delhi, India, 2005 (Bachelor of Medicine and Bachelor of Surgery (MBBS),)
Residency: Creighton University Medical Center, Omaha, NE, 2014 (Internal Medicine Residency )
Fellowship: University of Cincinnati Medical Center Cincinnati, Ohio, 2017 (Pulmonary and Critical Care)
Masters in Clinical & Translational Research: University of Cincinnati Cincinnati, OH, 2019
Certifications
American Board of Internal Medicine (Critical Care Medicine) (Certification Date: 10-18-2017 )
American Board of Internal Medicine (Certification Date: 08-13-2014 )
American Board of Internal Medicine (Pulmonary Disease) (Certification Date: 10-05-2016 )
Clinical Interests
Critical Care Medicine
Lung Disease
Pulmonary Disease
Rare Lung Disease
Sarcoidosis
Asbestosis
Bronchiolitis
Chronic Cough
Dyspnea
Histoplasmosis
Idiopathic Pulmonary Fibrosis
Interstitial Lung Disease (ILD)
Legionnaires' Disease (Legionellosis)
Pleurisy
Pneumonia
Pneumonitis
Pulmonary Fibrosis
Pulmonary Sarcoidosis
Respiration Disorders
Respiratory Syncytial Virus (RSV)
Respiratory Tract Disease
Respiratory Tract Infections
Shortness of Breath
Thoracic Cancer
Tuberculosis
Whooping Cough (Pertussis)
Specialities
Critical Care Medicine
Internal Medicine
Research and Practice Interests
Pulmonary and Critical Care
Research Support
Grant: #KIN-1902-2001 Investigators:Singla, Abhishek 06-01-2022 -05-31-2025 Kinevant Sciences, GmbH A Randomized, Double-blind, Placebo-controlled Phase 2 Study with Open-label Extension to Assess the Efficacy and Safety of Namilumab in Subjects with Chronic Pulmonary Sarcoidosis. Role:PI 322299.85 Hold Level:Industry
Grant: #LYT-100-2022-204 Investigators:Singla, Abhishek 03-07-2023 -03-06-2026 PureTech LYT 100, Inc. A RANDOMIZED, DOUBLE-BLIND, FOUR-ARM ACTIVE AND PLACEBO-CONTROLLED DOSE FINDING TRIAL TO EVALUATE THE EFFICACY, TOLERABILITY AND SAFETY DOSE RESPONSE OF LYT-100 IN PATIENTS WITH IDIOPATHIC PULMONA Role:PI 0.00 Hold Level:Industry
Grant: #PLN74809-000 Investigators:Singla, Abhishek 01-29-2024 -01-28-2027 Pliant Therapeutics, Inc. A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON) Role:PI 136993.23 Active Level:Industry
Publications
Peer Reviewed Publications
Singla A.; Kopras E.J.; Gupta N. (11-01-2019. ) Spontaneous pneumothorax and air travel in Pulmonary Langerhans cell histiocytosis: A patient survey.Respiratory Investigation, , 57 (6 ) ,582-589 More Information
Singla A.; Gupta N.; Apewokin S.; McCormack F. (11-02-2017. ) Sirolimus for the treatment of lymphangioleiomyomatosis.Expert Opinion on Orphan Drugs, , 5 (11 ) ,907-921 More Information